Epidemiology of Bacteremia at Two Tertiary ICUs in Switzerland

January 25, 2023 updated by: University Hospital Inselspital, Berne

Duration of Antimicrobial Treatment for Bloodstream Infections in Swiss Critically Ill Patients - Retrospective Double Center Study

The objectives of the retrospective cohort study is to describe the actual current practice of antibiotic treatment duration for bloodstream infections in critically ill patients at two tertiary hospitals (ICU Inselspital Bern and ICU CHUV Lausanne), to examine patient, pathogen and infectious syndrome factors associated with selection of shortened treatment duration, and to describe the expected time course of clinical resolution among bacteremic patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

395

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
      • Bern, Switzerland
        • Departement of Intensive Care Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patient is critically ill at the time the blood culture was collected and was treated at the ICU/IMC at the time of blood culture collection or has been admitted to ICU/IMC in the 48 hours after blood culture collection.

Description

Inclusion Criteria:

Patient has a positive blood culture with a pathogenic organism Patient is critically ill at the time the blood culture was collected as defined by the following:

  1. was treated at the ICU/IMC at the time of blood culture collection;
  2. or has been admitted to ICU/IMC in the 48 hours after blood culture collection

Exclusion Criteria:

  1. Patient has a single positive blood culture with a common contaminant organism:

    • coagulase negative staphylococci;
    • Bacillus spp.;
    • Corynebacterium spp.;
    • Propionibacterium spp.;
    • Aerococcus spp.;
    • Micrococcus spp.
  2. Explicit documentation that the patient does not want to participate in any study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Bern ICU
Diagnostic test: Blood Culture
Blood Culture
Lausanne ICU
Diagnostic test: Blood Culture
Blood Culture

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Antibiotic Treatment Duration
Time Frame: Hospital discharge, expected to be on average ca. 15-20 days
Days of adequate antibiotic treatment in Patients with Bacteremia
Hospital discharge, expected to be on average ca. 15-20 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Days of ICU stay
Time Frame: ICU discharge, expected to be on average ca. 5-15 days
Days of ICU Stay in Patients with Bacteremia
ICU discharge, expected to be on average ca. 5-15 days
Days of hospital stay
Time Frame: Hospital discharge, expected to be on average ca. 15-25 days
Days of Inhospital Stay in Patients with Bacteremia
Hospital discharge, expected to be on average ca. 15-25 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital Inselspital, Berne

Investigators

  • Principal Investigator: Josef Prazak, MD, PhD, University Hospital Inselspital, Berne

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2022

Primary Completion (Actual)

March 1, 2022

Study Completion (Actual)

March 30, 2022

Study Registration Dates

First Submitted

February 1, 2022

First Submitted That Met QC Criteria

February 1, 2022

First Posted (Actual)

February 11, 2022

Study Record Updates

Last Update Posted (Estimate)

January 26, 2023

Last Update Submitted That Met QC Criteria

January 25, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2021-02302

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bacteremia

Clinical Trials on Blood Culture

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe